The Patent Finder
BP

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

First filing 2018
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Previously recorded as Beijing Biocytogen Co., Ltd. (to 2021)

37 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next US patent term in the Biocytogen Pharmaceuticals (Beijing) Co., Ltd. portfolio ends in Jun 2037, and more of its terms end in 2037 (14) than in any other year. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2037
Next term end
27
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Feb 15 to 22, 2027 · next Feb 15
  • 1 fee due Nov 21, 2027
    The maintenance fee for Modified Immunoglobulins (US 11,987,615) comes due Nov 21, 2027. Unpaid by May 22, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 24, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 10,912,287Genetically Modified Mice Expressing Humanized PD-1
In force
 · High confidence
In forceHigh confidence
US 11,234,420Method for Constructing PD-1 Gene Modified Humanized Animal Model and Use Thereof
In force
 · High confidence
In forceHigh confidence
US 10,945,418Genetically Modified Non-Human Animal with Human or Chimeric PD-L1
In force
 · High confidence
In forceHigh confidence
US 11,071,290Genetically Modified Non-Human Animal with Human or Chimeric CTLA-4
In force
 · High confidence
In forceHigh confidence
US 11,096,383Method of Using a Genetically Modified Mouse That Expresses a Humanized CTLA-4 Gene
In force
 · High confidence
In forceHigh confidence
US 11,279,948Genetically Modified Non-Human Animal with Human or Chimeric OX40
In force
 · High confidence
In forceHigh confidence
US 11,317,611Genetically Modified Non-Human Animal with Human or Chimeric PD-L1
In force
 · High confidence
In forceHigh confidence
US 11,464,876Genetically Modified Mouse Comprising a Chimeric Tigit
In force
 · High confidence
In forceHigh confidence
US 11,505,806Genetically Modified Non-Human Animal with Human or Chimeric OX40
In force
 · High confidence
In forceHigh confidence
US 11,534,502Genetically Modified Non-Human Animal with Human or Chimeric TIGIT
In force
 · High confidence
In forceHigh confidence
10 of 37 patents shown.
Pro members see all 37.
Pro members: see all 37 patents
Also on record, not counted in the 37: 59 applications pending · 14 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited